Comparison of adjuvant 0.02% Chlorhexidine gluconate with 1% Povidone-Iodine in the management of fungal keratitis: A randomized controlled trial - NIL

Start Date01 Feb 2025

Sponsor / Collaborator-

NCT06465901 / Not yet recruitingNot ApplicableIIT

MARLIN: Stratified, Multi-arm, Multi-stage Factorial Randomised Platform Trial Aiming to Reduce the Incidence of Post-operative Surgical Site Infection (SSI).

MARLIN is a stratified, multi-arm, multi-stage factorial randomised platform trial aiming to reduce the incidence of post-operative surgical site infection (SSI).

Start Date01 Sep 2024

Sponsor / Collaborator

University of Birmingham

NCT06464770 / Not yet recruitingNot ApplicableIIT

Optimizing Infection Prophylaxis Prior to Shoulder Surgery

The goal of this interventional study is to determine the amount of skin C. acnes reduction with increased pressure during the chlorhexidine gluconate, brand name ChloraPrep, application. The main question it aims to answer is:
Does changing the pressure applied during the ChloraPrep application impact the amount of C. acnes bacteria on the skin after one hour? Researchers will compare ChloraPrep applied at a pressure similar to a gentle wipe to ChloraPrep applied at a pressure similar to a massage to see if wash the amount of C. acnes on the skin after one hour is different.
Participants will have one shoulder washed with ChloraPrep using pressure meant to impact the dermal layer, similar to a gentle wipe, and the other shoulder washed with ChloraPrep using pressure meant to impact the subdermal layer, similar to a massage. Participants will have swabs taken of their skin before the ChloraPrep application and again one hour after application to look for the amount of C. acnes on the skin.

Start Date01 Jul 2024

Sponsor / Collaborator

University of Washington

100 Clinical Results associated with Chlorhexidine gluconate

100 Translational Medicine associated with Chlorhexidine gluconate

100 Patents (Medical) associated with Chlorhexidine gluconate

2,330

Literatures (Medical) associated with Chlorhexidine gluconate

01 Mar 2024·Dimensions of critical care nursing : DCCN

Misuse of the P Value

Article

Author: Reynolds, Staci S ; Waldrop, Julee

Introduction:

Quantitative research and quality improvement (QI) both seek to improve care provided to patients. However, clinicians often blur the lines between how to appropriately analyze data from these methodologies. Clinicians may inappropriately use statistical analyses for QI initiatives, rather than using run and statistical process control (SPC) charts to analyze improvements in outcomes.

Objective:

The purpose of this article was to address the analytic methods used for QI initiatives in the clinical setting in an effort to show clinicians how to identify meaningful improvements in clinical practice.

Methods:

In this article, we provide an example comparing the same evidence-based practice/QI initiative (chlorhexidine gluconate bathing in a medical intensive care unit) using a quasi-experimental pretest/posttest research design with statistical analyses completed with t tests with analyses using run and SPC charts to show the data trended over time. Using a pretest/posttest design, chlorhexidine gluconate bathing compliance improved from 63% to 65%, a nonsignificant change, P = .075. These same data plotted on run and SPC charts, however, show a shift and a trend, indicating clinically significant improvements per QI methodologies.

Conclusion:

The example in this article highlights the pitfall of relying only on statistical analyses and P values to determine the importance of a clinical project, and provides a practical example for how run or SPC charts can be used to identify improvements over time.

01 Mar 2024·Archives of disease in childhood. Fetal and neonatal edition

2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheterisation: the ARCTIC randomised controlled feasibility trial

Article

Author: Soe, Aung ; Linsell, Louise ; Muthukumar, Priyadarsini ; Webber, Mark A ; King, Andrew ; Partlett, Christopher ; Pattnayak, Santosh ; Clarke, Paul ; Nichols, Amy ; Tremlett, Catherine ; Harizaj, Helen ; Heath, Paul T ; Juszczak, Ed ; Bell, Jennifer L

Objective:

Catheter-related sepsis (CRS) is a major complication with significant morbidity and mortality. Evidence is lacking regarding the most appropriate antiseptic for skin disinfection before percutaneous central venous catheter (PCVC) insertion in preterm neonates. To inform the feasibility and design of a definitive randomised controlled trial (RCT) of two antiseptic formulations, we conducted the Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) feasibility study to assess catheter colonisation, sepsis, and skin morbidity.

Design:

Feasibility RCT.

Setting:

Two UK tertiary-level neonatal intensive care units.

Patients:

Preterm infants born <34 weeks’ gestation scheduled to undergo PCVC insertion.

Interventions:

Skin disinfection with either 2% chlorhexidine gluconate (CHG)-aqueous or 2% CHG-70% isopropyl alcohol (IPA) before PCVC insertion and at removal.

Primary outcome:

Proportion in the 2% CHG-70% IPA arm with a colonised catheter at removal.

Main feasibility outcomes:

Rates of: (1) CRS, catheter-associated sepsis (CAS), and CRS/CAS per 1,000 PCVC days; (2) recruitment and retention; (3) data completeness.

Safety outcomes:

Daily skin morbidity scores recorded from catheter insertion until 48 hours post-removal.

Results:

116 babies were randomised. Primary outcome incidence was 4.1% (95% confidence interval: 0.9% to 11.5%). Overall catheter colonisation rate was 5.2% (5/97); CRS 2.3/1000 catheter days; CAS 14.8/1000 catheter days. Recruitment, retention and data completeness were good. No major antiseptic-related skin injury was reported.

Conclusions:

A definitive comparative efficacy trial is feasible, but the very low catheter colonisation rate would make a large-scale RCT challenging due to the very large sample size required. ARCTIC provides preliminary reassurance supporting potential safe use of 2% CHG-70% IPA and 2% CHG-aqueous in preterm neonates.

Trial registration number:

ISRCTN82571474.

Scientific reports

Effects of mouthwash on periodontal pathogens and glycemic control in patients with type 2 diabetes mellitus

Article

Author: Takagi, Misato ; Okuda, Makoto ; Itoh, Naoto ; Ochiai, Marin ; Nakano, Kazuhiko ; Suehiro, Yuto ; Matayoshi, Saaya ; Okawa, Rena ; Tojo, Fumikazu ; Kadono, Maika ; Mikasa, Yusuke ; Nomura, Ryota ; Itoh, Yoshito

Abstract:

Periodontitis is known to be associated with type 2 diabetes mellitus (T2DM), and gargling with mouthwash is known to reduce the incidence of periodontitis by inhibiting periodontal pathogens. However, the effects of mouthwash on oral and systemic conditions in patients with T2DM remain unknown. In this study, we investigated the effects of gargling with mouthwash on the number of red complex species, including Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia, and HbA1c levels in patients with T2DM. Patients were instructed to gargle with water for 6 months, followed by gargling with mouthwash containing chlorhexidine gluconate for the subsequent 6 months. At each clinic visit, saliva was collected and bacterial DNA was extracted to detect red complex species using the polymerase chain reaction technique. The HbA1c level was determined using a blood sample. The number of red complex species significantly decreased in younger or male patients who gargled with mouthwash. Furthermore, HbA1c levels significantly decreased in younger patients or patients with higher HbA1c levels who gargled with mouthwash. These results suggest that gargling with mouthwash reduces the number of red complex species and improves the hyperglycemic status in patients with T2DM, especially younger patients.

News (Medical) associated with Chlorhexidine gluconate

21 May 2024

·www.biospace.com

Access Vascular Announces New Bacterial Adhesion Data at INS 2024

Data presented at the Infusion Nurses Society Annual Scientific Meeting demonstrates limited bacterial adhesion and thrombus accumulation with MIMIX™ material BILLERICA, Mass.--(BUSINESS WIRE)-- Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from new data showing a reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICCs) and midline catheters with AVI’s MIMIX® hydrophilic biomaterial (HBM) compared with conventional catheters. The new data, shared May 19 at the annual scientific meeting of the Infusion Nurses Society in Kansas City, Mo., compared bacterial adhesion on two polyurethane-based catheters with the HBM. The HBM demonstrated a 99.999 percent reduction in bacterial adhesion compared with both a standard polyurethane catheter and a Chlorhexidine gluconate (CHG)-coated polyurethane material.1 “These results add to our compendium of MIMIX® evidence showing lower rates of the most common and costly complications associated with vascular access devices,” said James Biggins, founder and CEO of Access Vascular. “We have now shown that our HBM-based catheters significantly reduce bacterial adhesion, compared to all major catheter materials currently available, and may be the key in the fight against catheter-associated bloodstream infections.” The study also demonstrated a 97 percent reduction in surface thrombus accumulation for the HBM catheter material compared with the CHG-coated polyurethane catheter, and 98 percent versus standard polyurethane, echoing results shared in multiple prior studies demonstrating the thromboresistance of HBM catheters.2,3 “These new data reinforce my belief that this unique material can have a substantial impact on reducing complications related to vascular access, such as bloodstream infections,” said Lee Steere, nurse manager for IV Therapy Services at Hartford Hospital in Connecticut. “Our facility has logged zero catheter-related bloodstream infections since we began using AVI’s HydroMID® catheters in early 2023.” Central-line associated bloodstream infections (CLABSI) can increase hospital length of stay (LOS) by more than 17 days, increase costs by more than $55,000 per admission, and pose a more than 3.5-fold increased risk of mortality in ICU patients.4 A single CLABSI case can cost a hospital more than in $1 million in lost revenue, not including impacts on CMS reimbursement, and lead to myriad patient complications.5,6 Rates of CLABSI infection have risen as much as 51 percent since the COVID-19 pandemic.7 About Access Vascular Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and the complications that come with it. Our award-winning, FDA-cleared products are HydroPICC® and HydroMID®. For more information, please visit , and follow us on LinkedIn. [1] Data collected using in vitro and static models. Data on Access Vascular. Pre-clinical in vitro valuations do not necessarily predict clinical performance with respect to thrombus formation. [2] Bunch J. A retrospective assessment of peripheral midline failures focusing on catheter composition. J InfusNurs. Sept/Oct 2022; 45(5):270-27. [3] Bunch J. A retrospective, comparative, clinical study of occlusion rate of peripherally inserted central catheters fabricated of poly(vinyl alcohol)-based hydrogel composite. J Mater Sci Mater Med. 2023 Jul 21;34(7):34. [4] Yu, C, et al. Characteristics, costs, and outcomes associated with central-line–associated bloodstream infection and hospital-onset bacteremia and fungemia in US hospitals. Infect. Control Hosp. Epidemiol. 2023 July 44:12 [5] Shepard, J. Could the prevention of health care-associated infections increase hospital cost? The financial impact of health care-associated infections from a hospital management perspective. J of Infection Control; 48 (2020) 255−260. [6] Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: a meta-analysis. Crit Care Med 2009; 37:2283-9. [7] Fakih, M., et al. (2021). Coronavirus disease 2019 (COVID-19) pandemic, central-line-associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): The urgent need to refocus on hardwiring prevention efforts. Infection Control Hospital Epidemiology, 1-6. Doi:10.1017/ice.2021.70 View source version on businesswire.com: Contacts Brad Perriello Circle Hill Communications 617.817.1385 brad@circlehillcommunications.com Source: Access Vascular, Inc. View this news release online at:

Clinical Result

01 Feb 2024

·www.sciencedaily.com

Large multicenter clinical trial finds that antiseptic containing iodine reduces surgical-site infections in patients with extremity fractures

A large multicenter clinical trial found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. Researchers believe the results of the study of nearly 8,500 patients across the United States and Canada could prevent thousands of surgical-site infections each year. A large multicenter clinical trial co-led by University of Maryland School of Medicine researchers large multicenter clinical trial co-led by University of Maryland School of Medicine researchers found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. The results of the study of nearly 8,500 patients across the United States and Canada were published today in the New England Journal of Medicine. The study -- which compared the two most commonly used alcohol-based solutions, one with iodine povacrylex, and the other with chlorhexidine gluconate -- may prompt changes in the type of antiseptic orthopaedic surgeons use to prepare the skin to repair fractures. Researchers saw the benefit in patients with closed, or simple fractures, where the skin remains intact, but not in compound fractures with open wounds, although they noted that using the iodine preparation was not harmful to these open-fracture patients. "Our results suggest that the use of iodine povacrylex in alcohol as a preoperative skin antiseptic could prevent surgical-site infections in thousands of patients with closed fractures each year," said co-principal investigator Gerard Slobogean, MD, MPH, an Associate Professor of Orthopaedics and Director of Clinical Research in the Department of Orthopaedics at the University of Maryland School of Medicine (UMSOM). He is also an orthopaedic trauma surgeon at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center (UMMC). Each year, more than a million Americans suffer a broken bone in the arm, leg, or pelvis that requires surgery, and about 3 percent of these patients develop a surgical-site infection. The source of bacteria could be the patient's skin, the injury environment, or from the hospital. Although some guidelines have favored using chlorhexidine gluconate over other iodine products, there has not been a consensus on the most effective agent. Dr. Slobogean and his colleagues believe that the trial, which included 8,485 patients treated at 25 trauma centers, is the largest randomized clinical trial ever conducted to compare the two antiseptics, which allowed them to detect important differences in infection. They said that the findings may also be relevant to other surgical specialties. More than 6,700 patients who had surgery to treat a closed lower extremity or pelvic fracture and 1,700 patients who had surgery to treat an open fracture participated in the study. The R Adams Cowley Shock Trauma Center and University of Maryland Capital Region Health's (UM Capital) trauma center in Largo, Md., were among more than two dozen trauma centers to enroll patients. UMMC and UM Capital are part of the 11-hospital University of Maryland Medical System (UMMS). "The results of this well-designed study provide some long overdue clarity to orthopaedic trauma surgeons with respect to which commonly used antiseptic skin preparation is more effective when preparing for fracture surgery," said study co-author Todd Jaeblon, DO, an Associate Professor of Orthopaedics at UMSOM who treats patients at UM Capital. Of the 3,205 closed-fracture patients who received 0.7% iodine povacrylex in 74% isopropyl alcohol, 77, or 2.4 percent, developed a surgical-site infection. That compares with 108, or 3.3 percent of the 3,272 patients who received 2% chlorhexidine gluconate in 70% isopropyl alcohol. In patients with open fractures, the number of patients who developed infections was similar between the two antiseptics -- 54 patients, or 6.5 percent of 825 patients in the iodine group, and 60 patients, or 7.3% of the 826 patients in the chlorhexidine group. "Extremity fractures and the challenging surgical-site infections that result from them pose a significant health care burden on our nation," said Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM, and Vice President for Medical Affairs, University of Maryland, Baltimore. "This pragmatic trial tested two widely used antiseptics, and its crossover design minimized selection bias. It also enrolled patients from 25 diverse hospitals in the U.S. and Canada, which improved the generalizability of the results; the strength of the study design could serve as a model for other researchers." The PREPARE (Pragmatic Randomized Trial Evaluating Preoperative Alcohol Skin Solutions in Fractured Extremities) trial was jointly led by UMSOM and McMaster University of Hamilton, Ontario. It was funded with $11.2 million from the Patient-Centered Outcomes Research Institute (PCORI), with additional support from the Canadian Institutes of Health Research. "This trial represents a highly successful collaboration between McMaster University, the University of Maryland School of Medicine, and 25 trauma centers across Canada and the United States," said co-principal investigator Sheila Sprague, PhD, an Associate Professor and Research Director at McMaster University. "This multidisciplinary approach allowed us to quickly and efficiently address an important clinical research question that will lead to the prevention of thousands of infections each year. Importantly, our collaborations will continue to grow to address other unanswered questions in orthopaedic trauma surgery." This is the second clinical study co-led by Dr. Slobogean and Dr. Sprague aimed at closing the gaps in the medical literature on the most effective infection-control techniques in orthopaedic surgery. In October 2022, they published the results of the Aqueous-PREP trial in The Lancet. They concluded that the choice of an aqueous antiseptic solution -- either 10% povidone-iodine or 4% chlorhexidine gluconate -- does not alter the risk of surgical-site infection for patients with an open fracture. Both Aqueous-PREP and PREPARE follow a master protocol called PREP-IT (Program of Randomized Trials to Evaluate Preoperative Antiseptic Skin Solutions in Orthopaedic Trauma) to test infection prevention techniques in trials that will provide crucial evidence to help guide surgical practices. This research was supported by the PREP-IT investigators, which includes a network of over 200 physicians, allied health care professionals, trauma patients, and clinical researchers.

Clinical ResultClinical Study

13 Dec 2023

·www.businesswire.com

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--( BUSINESS WIRE )--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confirmed that it has more than doubled the number of Steriwave ® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global focus on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine’s photodisinfection technology. The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%, 2 and very poor compliance. 3 Carolyn Cross, CEO of Ondine, commented, "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024.” The five-minute Steriwave nasal decolonization procedure is easy to incorporate into the pre surgery procedures. It is painless and very well received by patients who are often intrigued by the process. There have been no reports of serious side effects as a result of Steriwave usage. Steriwave has been used by more than 150,000 patients, including at Vancouver General Hospital where its use has been associated with a significant reduction in HAIs across major surgeries. 4,5 As well as growing its commercial activities, the company continues to work closely with HCA – the largest hospital group in the United States – to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine’s submission to the FDA for approval. The company already has approval for Steriwave in Canada, the UK, the EU, and Mexico. Implementing nasal decolonization prior to major surgery to reduce HAIs is recommended by leading medical bodies, including the World Health Organization, 6 the Society for Healthcare Epidemiology of America (SHEA), 7 and NICE. 8 The nose is the major reservoir of pathogens and the majority of surgical site infections (SSIs) and bloodstream infections have been traced back to bacteria in the patient’s nose. 9 A patient with a surgical site infection (SSI) will, on average, spend 7 to 11 days longer in the hospital, significantly increasing costs and lengthening patients' recovery. 10 While currently focusing on nasal decolonization, Ondine’s patented photodisinfection technology will be developed to prevent and treat a wide variety of topical infections. About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life science company pioneering the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. 1 Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22. doi: 10.1586/erp.09.53. PMID: 19817525; PMCID: PMC2827870. 2 Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother . 2015;70(10):2681-2692. doi:10.1093/jac/dkv169 3 Hansen D, Patzke PI, Werfel U, Benner D, Brauksiepe A, Popp W. Success of MRSA eradication in hospital routine: depends on compliance. Infection. 2007 Jun;35(4):260-4. doi: 10.1007/s15010-007-6273-y. Epub 2007 Jul 23. PMID: 17646910. 4 Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014 Oct;88(2):89-95. doi: 10.1016/j.jhin.2014.06.017. Epub 2014 Aug 1. Erratum in: J Hosp Infect. 2015 Sep;91(1):93. PMID: 25171975. 5 Moskven E, Banaszek D, Sayre E, Gara A, Bryce E, Wong T, Ailon T, Charest-Morin R, Dea N., Dvorak M, Fisher C, Kwon B, Paquette S, Street J. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6), E550–E560. https://doi.org/10.1503/cjs.016922 6 World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. World Health Organization; 2016. Available at: https://www.who.int/publications/i/item/9789241550475 . Accessed December 12, 2023. 7 Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67 8 National Institute for Health and Care Excellence (NICE). NICE Surgical Site Infections: Prevention and Treatment. NICE; 2019. Available at: https://www.nice.org.uk/guidance/ng125 . Accessed December 12, 2023. 9 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102. PMID: 11136954. 10 Seidelman JL, Mantyh CR, Anderson DJ. Surgical Site Infection Prevention: A Review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

Phase 3Drug Approval

100 Deals associated with Chlorhexidine gluconate

External Link

KEGG	Wiki	ATC	Drug Bank
D00858	Chlorhexidine gluconate	A01AB03 S03AA04 S02AA09	DB00878

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Periodontitis	US	Dexcel Pharma Technologies Ltd.	15 May 1998
Skin Diseases, Bacterial	AU	Bridgewest Perth Pharma Pty Ltd.	13 Aug 1991
Gingival Hemorrhage	US	3M Co.	13 Aug 1986
Gingivitis	US	3M Co.	13 Aug 1986
Bacterial Infections	US	Mölnlycke Health Care AB	17 Sep 1976
Disinfectants	JP	Sumitomo Pharma Co., Ltd.	22 Sep 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peri-Implantitis	Phase 3	US	Dexcel Pharma Technologies Ltd.	01 Jul 2014
Peri-Implantitis	Phase 3	DE	Dexcel Pharma Technologies Ltd.	01 Jul 2014
Peri-Implantitis	Phase 3	IL	Dexcel Pharma Technologies Ltd.	01 Jul 2014
Peri-Implantitis	Phase 3	GB	Dexcel Pharma Technologies Ltd.	01 Jul 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03326726 (CTgov)	Phase 2	Skin Diseases	30	chlorhexidine gluconate	srsayhotqf(sgzcvmkfza) = vvvbbclbok qjklzstwpy (nlfskmaday, jyhxjgzeys - tuofcrjhxo) View more	-	28 Sep 2023
NCT04048356 (CTgov)	Phase 3	Urinary Incontinence \| Postoperative infection \| Pelvic Floor Disorders ... View more	137	Vaginal scrub, to be applied vaginally (Chlorhexidine Gluconate)	lfgrccigwz(lmgvmoxrgw) = idinhwhkgx wjatgwbvam (ewyrvxwglf, ffhhslgryq - lhimuwpdyl) View more	-	10 Jul 2023
				Vaginal scrub, to be applied vaginally (Povidone Iodine)	lfgrccigwz(lmgvmoxrgw) = hmcskgpdsj wjatgwbvam (ewyrvxwglf, nlmwovtilh - vkqxcltemv) View more
NCT03385304 (Aqueous-PREP, CTgov)	Phase 4	Surgical Wound Infection \| Fractures, Open	1,638	10% povidone-iodine (1% free iodine) in purified water+4% chlorhexidine gluconate (CHG) in purified water (10% Povidone-iodine (1% Free Iodine) in Purified Water)	qkpdwrhqjq(rsbhizyvwg) = fsdlnpspft upbzlwjqag (vinvsgvofc, xvrbplhybh - vmeollyunh) View more	-	31 Mar 2023
				10% povidone-iodine (1% free iodine) in purified water+4% chlorhexidine gluconate (CHG) in purified water (4% Chlorhexidine Gluconate (CHG) in Purified Water)	qkpdwrhqjq(rsbhizyvwg) = jsmwplmjrr upbzlwjqag (vinvsgvofc, durfxfktcz - evbeumoqyr) View more
NCT03423147 (CTgov)	Phase 2	Surgical Wound Infection \| Cross Infection	319	4% Chlorhexidine gluconate vaginal scrub (Chlorhexidine Gluconate Vaginal Scrub and Cloth)	valxanhgnn(sdhsokrhwn) = ciknwafpnh raukcrnrlf (cmxyrnpsuj, dqvubvjqbi - fxotorudny) View more	-	23 Mar 2023
				2% chlorhexidine gluconate cloth (Standard Treatment)	valxanhgnn(sdhsokrhwn) = rkaohpmymn raukcrnrlf (cmxyrnpsuj, oysewgldpw - oqfznpfpjb) View more
NCT02598778 (CTgov)	Phase 2	Dental Caries	12	Chlorhexidine gluconate (0.12%) (Chlorhexidine Gluconate (0.12%))	avabtyygmr(qhhvewertp) = obrgdrdirq zstjqrbaqp (nufzdpymna, foqsmcdczn - mzjroxgphu) View more	-	31 Oct 2022
				Sodium Fluoride (0.05%) (Sodium Fluoride (0.05%))	avabtyygmr(qhhvewertp) = pqgywiiyxr zstjqrbaqp (nufzdpymna, asjjqgatpv - oalbawyuzd) View more
NCT03883828 (ASCO2022) Manual	Phase 2/3	Radiodermatitis	76	mupirocin+Chlorhexidine gluconate	lchmsgqfwr(nghvypdgih) = refwqwfpaj dnvqiwpakd (osybvkxkce ) View more	Positive	08 Jun 2022
				standard of care	lchmsgqfwr(nghvypdgih) = xxycsxgpld dnvqiwpakd (osybvkxkce ) View more
NCT04748783 (CTgov)	Phase 2	COVID-19	2	Water (Sterile Water)	froykplxem(egoxldgsuc) = oexohhztik xicoukdivu (runcpkamut, yeqrnslmyd - tfkdjjnkco) View more	-	16 Feb 2022
				Peroxyl (Peroxyl)	froykplxem(egoxldgsuc) = fkekbxhkth xicoukdivu (runcpkamut, azasuzmjog - vlncxlzmue) View more
NCT02395614 (CTgov)	Not Applicable	Surgical Wound Infection \| Breast Cancer	88	Chlorhexidine irrigation (Chlorhexidine Irrigation)	hwlzrrqkvk(uwzchrcnzs) = ivefvfpzvd jjhapgkeuo (wjkkvhrbwy, zvslkmipfu - jbzirezejr) View more	-	26 Jan 2022
				cefazolin+bacitracin+gentamicin (Triple Antibiotic Irrigation)	hwlzrrqkvk(uwzchrcnzs) = jfwtowmgqa jjhapgkeuo (wjkkvhrbwy, tweiqxsbed - rkuytprdap) View more
NCT04048356 (Pubmed \| Am J Obstet Gynecol)	Phase 3	-	119	Chlorhexidine gluconate	uzfvmrbofd(nylrmrcrvq) = hepoxljira pcvzbohjip (ugopcpywtz )	-	29 Dec 2021
				Povidone iodine	uzfvmrbofd(nylrmrcrvq) = vcrfsvimdq pcvzbohjip (ugopcpywtz )
NCT02326467 (CTgov)	Phase 1	Hypersensitivity \| Exanthema \| Infectious Diseases	10	Chlorhexidine gluconate	exmrcopmqt(uiwwzgnysg) = hqnpweztdi eszsmtpaho (htjhckuhxt, ppbdcdfppk - tyjwryiijb) View more	-	27 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis